EGFR VEDVsPNU+EDVs40 mer
Alternative Names: D682-carrying EDV™ - EnGeneIC; Designer EDVTM; E-EDV-D682; E-EDV-D682 - EnGeneIC; EGFR VEDVsPNU; EGFR-VEDVsPNU-EnGeneIC; PNU-159682Latest Information Update: 13 Dec 2023
At a glance
- Originator EnGeneIC
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Pancreatic cancer; Solid tumours
Most Recent Events
- 07 Dec 2023 EGFR VEDVsPNU+EDVs40 mer receives Fast track status from the US FDA for Pancreatic cancer
- 07 Dec 2023 US FDA approves IND application for EGFR VEDVsPNU+EDVs40 mer in Pancreatic cancer
- 07 Dec 2023 EnGeneIC plans a phase IIa trial for Pancreatic cancer (Second-line therapy or greater) in USA (IV)